Development and Characterization of Drug-Loaded Self-Solidnano-Emulsified Drug Delivery System for Treatment of Diabetes

Abstract

Embelin and gliclazide administration to diabetic rats cause a highly significant decline in the blood glycated hemoglobin, serum glucose and nitric oxide activity with a concomitant increase in the serum insulin level. The aim of present work was the development and characterization of self-solid nano-emulsified drug delivery system (SNEDDS) formulation of embelin in combination with gliclazide for the determination of antidiabetic effect in Wistar rats. In this connection, we prepared SNEDDS by using an oil:surfactant mixture ratio of [Capmul® MCM: Kolliphor® HS 15: PEG 400 (2:1)] and encapsulated the drug combination in this system. The in-vitro characterization of optimized liquid SNEDDS containing 40% surfactant mixture and 60% oil) was performed and the SNEDDS were found to have particle size of 159.9nm, polydispersity index of 0.289 and zeta potential of -34.35mV. Percentage cumulative release from this formulation was 94.26±3.80% for gliclazide and 90.63±3.67% for embelin in phosphate buffer (pH 7.4) compared to 39.09±1.38% and 34.29±1.20% from plain drug suspension. The embelin (30mg/kg)+gliclazide (10mg/kg) loaded SNEDDS was found to be effective in reversing streptozotocin-induced hyperglycemia as compared to pure drugs in Wistar rats.